Cargando…

Very rare case of Graves’ disease with resistance to methimazole: a case report and literature review

BACKGROUND: Methimazole (MMI) is used to treat hyperthyroidism in Graves’ disease. It is rare to encounter patients in whom hyperthyroidism cannot be controlled using high doses of MMI. Case presentation: A 21-year-old woman was referred to our hospital because of MMI-resistant Graves’ disease. Alth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Yusaku, Hiromura, Munenori, Terasaki, Michishige, Kushima, Hideki, Ohara, Makoto, Fukui, Tomoyasu, Takahashi, Yasuyoshi, Yamagishi, Sho-ichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944538/ https://www.ncbi.nlm.nih.gov/pubmed/33682498 http://dx.doi.org/10.1177/0300060521996192

Ejemplares similares

Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2
por: Hiromura, Munenori, et al.
Publicado: (2022)

A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression
por: Terasaki, Michishige, et al.
Publicado: (2020)

Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling
por: Mori, Yusaku, et al.
Publicado: (2019)

Anti-inflammatory and atheroprotective properties of glucagon
por: Osaka, Naoya, et al.
Publicado: (2020)

AGE-RAGE Axis Stimulates Oxidized LDL Uptake into Macrophages through Cyclin-Dependent Kinase 5-CD36 Pathway via Oxidative Stress Generation
por: Yashima, Hironori, et al.
Publicado: (2020)

Comparison of positive rates between glutamic acid decarboxylase antibodies and ElisaRSR™ 3 Screen ICA™ in recently obtained sera from patients who had been previously diagnosed with slowly progressive type 1 diabetes
por: Takehana, Nobuaki, et al.
Publicado: (2023)

The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis
por: Kushima, Hideki, et al.
Publicado: (2017)

Luseogliflozin inhibits high glucose-induced TGF-β2 expression in mouse cardiomyocytes by suppressing NHE-1 activity
por: Osaka, Naoya, et al.
Publicado: (2022)

Glucose Variability is Independently Correlated with Serum Level of Pigment Epithelium-Derived Factor in Type 2 Diabetes
por: Fujikawa, Tomoki, et al.
Publicado: (2021)

Association of Hemoglobin A1c, 1,5-Anhydro-d-Glucitol and Glycated Albumin with Oxidative Stress in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study
por: Kohata, Yo, et al.
Publicado: (2020)

Pancreatic fat accumulation evaluated by multidetector computed tomography in patients with type 2 diabetes
por: Fukase, Ayako, et al.
Publicado: (2020)

Combination Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor and a Dipeptidyl Peptidase-4 Inhibitor Additively Suppresses Macrophage Foam Cell Formation and Atherosclerosis in Diabetic Mice
por: Terasaki, Michishige, et al.
Publicado: (2017)

Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice
por: Terasaki, Michishige, et al.
Publicado: (2015)

Nesfatin-1 suppresses peripheral arterial remodeling without elevating blood pressure in mice
por: Mori, Yusaku, et al.
Publicado: (2019)

Prospective randomized comparative study of the effect of pemafibrate add‐on or double statin dose on small dense low‐density lipoprotein‐cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy
por: Hirano, Tsutomu, et al.
Publicado: (2023)

A Dipeptidyl Peptidase-4 Inhibitor Suppresses Macrophage Foam Cell Formation in Diabetic db/db Mice and Type 2 Diabetes Patients
por: Terasaki, Michishige, et al.
Publicado: (2018)

SMTP-44D Inhibits Atherosclerotic Plaque Formation in Apolipoprotein-E Null Mice Partly by Suppressing the AGEs-RAGE Axis †
por: Terasaki, Michishige, et al.
Publicado: (2023)

Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
por: Terasaki, Michishige, et al.
Publicado: (2021)

Association of glucose and blood pressure variability on oxidative stress in patients with type 2 diabetes mellitus and hypertension: a cross-sectional study
por: Ohara, Makoto, et al.
Publicado: (2019)

Control of Graves’ hyperthyroidism with very long-term methimazole treatment: a clinical trial
por: Azizi, Fereidoun, et al.
Publicado: (2021)

Two Cases of Methimazole-Induced Insulin Autoimmune Syndrome in Graves' Disease
por: Roh, Eun, et al.
Publicado: (2013)

A Rare Case of Anaphylaxis to Methimazole in a Patient With Graves’ Disease
por: Garg, Dave, et al.
Publicado: (2021)

FRI505 A Rare Case Of Methimazole Induced Grave Agranulocytosis
por: Barua, Nabonita, et al.
Publicado: (2023)

Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
por: Nagaike, Hiroe, et al.
Publicado: (2019)

Pheochromocytoma presenting with severe hyperglycemia and metabolic acidosis following intra-articular glucocorticoid administration: a case report
por: Tomoyasu, Masako, et al.
Publicado: (2019)

Methimazole-Induced Pleural Effusion in the Setting of Graves' Disease
por: Khine, Le Yu, et al.
Publicado: (2019)

Emphysematous cystitis in an elderly Japanese patient with type 2 diabetes mellitus
por: Yashima, Hironori, et al.
Publicado: (2019)

Adverse Events Associated with Methimazole Therapy of Graves' Disease in Children
por: Rivkees, Scott A., et al.
Publicado: (2010)

Polyarthritis Caused by Methimazole in Two Japanese Patients with Graves’ Disease
por: Nihei, Hiroko, et al.
Publicado: (2013)

A Case of Hypocalcemia with Severe Vitamin D Deficiency following Treatment for Graves' Disease with Methimazole
por: Miyashita, Kazuyuki, et al.
Publicado: (2013)

Efficacy of low-dose methimazole in control of multiple relapses of Graves’ hyperthyroidism: a case report
por: Azizi, Fereidoun, et al.
Publicado: (2021)

SUN-517 Methimazole-Induced Neutropenia in Premature Twins with Graves’ Disease
por: Ballestas, Estefania Rodriguez, et al.
Publicado: (2020)

Methimazole Desensitization in a 4-Year-Old With Refractory Graves Disease
por: Schneider Aguirre, Rebecca, et al.
Publicado: (2021)

Antithyroid arthritis syndrome caused by methimazole in a patient with Graves’ disease
por: Kawasumi, Muneo, et al.
Publicado: (2023)

Methimazole-induced insulin autoimmune syndrome in Graves' disease with hypokalemia: A case report and literature review
por: Han, Rongfeng, et al.
Publicado: (2020)

Insulin autoimmune syndrome induced by methimazole in a Korean girl with Graves' disease
por: Lee, Sun Hee, et al.
Publicado: (2013)

Impact of Methimazole Treatment on Magnesium Concentration and Lymphocytes Activation in Adolescents with Graves’ Disease
por: Klatka, Maria, et al.
Publicado: (2013)

Case report: hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in young Taiwanese woman with Graves’ disease
por: Wu, Hsuan-Yu, et al.
Publicado: (2022)

Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
por: Matsushita, Rie, et al.
Publicado: (2010)

Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ disease
por: Puthenpura, Vidya, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i183pombplcn78lpm87frl9hgg